CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.
If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...
CRISPR-based gene editing revolutionized medicine—what's next for the firm that helped develop it?
CRISPR-Cas 9 is a gene-editing tool that made it possible to rewrite any organism's genetic code and tackle genetic diseases more effectively. Known as genetic scissors, CRISPR identifies a DNA ...
If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...
CRISPR was one of the most influential breakthroughs of the last decade, but it's still imperfect. While the gene editing tool is already helping people with genetic ailments, scientists are also ...
Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...
Instead of pulling cells out of the body, editing them, and putting them back in, scientists have now found a way to send CRISPR tools directly to specific cells inside living animals. By wrapping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results